Bessemer Group
AVEO

Bessemer Group’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Bessemer Group’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-918
Closed -$10K – 1583
2014
Q3 		$10K Buy
+918
New +$11.7K ﹤0.01% 1090
2013
Q3 		– Sell
-691
Closed -$17K – 1417
2013
Q2 		$17K Buy
+691
New +$29.5K ﹤0.01% 955

Other funds holding AVEO

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DVC
Deer VI & Co Larchmont, New York $2.23M AUM 9.32% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
GX
Greylock XI Cambridge, Massachusetts $7.71M AUM 28.23% 1-Year Est. Return

Bessemer Group's AVEO Position: Q4 2014 in Review

Bessemer Group sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2014, closing a stake of 918 shares — an estimated $10K sold.

Bessemer Group first reported a position in AVEO in Q2 2013 and held it in 2 quarters. The position peaked at $17K in Q2 2013. 51 funds tracked by Wall St. Rank hold AVEO as of Q4 2014.

  • Bessemer Group reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Bessemer Group sold 918 AVEO Pharmaceuticals, Inc. shares in Q4 2014, an estimated $10K.
  • Bessemer Group first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 2 quarters.
  • Bessemer Group's AVEO Pharmaceuticals, Inc. position peaked at $17K in Q2 2013.
  • 51 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2014.

Based on Bessemer Group's 13F filing for Q4 2014, filed 17 Feb 2015.